Enveloped virus-like particles as vaccines against pathogenic arboviruses

Biotechnology Journal

Volumn 10, Issue 5, 2015, Pages 659-670

  Pijlman, Gorben P ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Arbovirus; Baculovirus expression system; Chikungunya; Vaccine; Virus like particle

Indexed keywords

ACCIDENT PREVENTION; ANIMALS; BIOTECHNOLOGY; CELL CULTURE; CELLS; CYTOLOGY; GLYCOPROTEINS; HEALTH RISKS; MANUFACTURE; VACCINES; VETERINARY MEDICINE; VIRUSES;

ARBOVIRUS; BACULOVIRUS EXPRESSION SYSTEMS; CHIKUNGUNYA; LARGE SCALE MANUFACTURE; POST-TRANSLATIONAL MODIFICATIONS; PRE-CLINICAL TESTING; REALISTIC POTENTIALS; VIRUS-LIKE PARTICLES;

DISEASES;

ENVELOPED VIRUS LIKE PARTICLE VACCINE; GLYCOPROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS LIKE PARTICLE VACCINE; VIRUS PROTEIN;

ARBOVIRUS; BACULOVIRUS EXPRESSION SYSTEM; BIOTECHNOLOGICAL PRODUCTION; BUNYAVIRIDAE; BUNYAVIRUS INFECTION; DRUG PURIFICATION; FLAVIVIRIDAE; FLAVIVIRIDAE INFECTION; HUMAN; INSECT CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PROCESSING; REVIEW; TOGAVIRIDAE; TOGAVIRUS INFECTION; VACCINE PRODUCTION; VIRUS ENVELOPE; VIRUS INFECTION; ALPHAVIRUS INFECTIONS; ANIMAL; BIOSYNTHESIS; GENETICS; IMMUNOLOGY; METABOLISM; PARASITE VECTOR; VETERINARY; VIROLOGY;

ANIMALIA; ARBOVIRUS; ARTHROPODA; BUNYAVIRIDAE; FLAVIVIRIDAE; HEXAPODA; JAPANESE ENCEPHALITIS VIRUS; TOGAVIRIDAE;

ALPHAVIRUS INFECTIONS; ANIMALS; ARBOVIRUSES; ARTHROPOD VECTORS; HUMANS; VACCINES, VIRUS-LIKE PARTICLE; VIRAL ENVELOPE PROTEINS;

EID: 84928828289     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201400427     Document Type: Review

References (98)

1. Weaver, S. C., Reisen, W. K., Present and future arboviral threats. Antiviral Res. 2010, 85, 328-345.
2. Chamberlain, R. W., Arboviruses, the arthropod-borne animal viruses. Curr. Top. Microbiol. Immunol. 1968, 42, 38-58.
3. Coffey, L. L., Forrester, N., Tsetsarkin, K., Vasilakis, N., Weaver, S. C., Factors shaping the adaptive landscape for arboviruses: Implications for the emergence of disease. Future Microbiol. 2013, 8, 155-176.
4. Bidaisee, S., Macpherson, C. N., Zoonoses and one health: A review of the literature. Parasitol. Res 2014, 2014, 874345.
5. Ishikawa, T., Yamanaka, A., Konishi, E., A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine 2014, 32, 1326-1337.
6. Nalca, A., Fellows, P. F., Whitehouse, C. A., Vaccines and animal models for arboviral encephalitides. Antiviral Res. 2003, 60, 153-174.
7. Metz, S. W., Pijlman, G. P., Arbovirus vaccines; opportunities for the baculovirus-insect cell expression system. J. Invertebr. Pathol. 2011, 107Suppl, S16-S30.
8. Roy, P., Noad, R., Virus-like particles as a vaccine delivery system: Myths and facts. Adv. Exp. Med. Biol. 2009, 655, 145-158.
9. Roldao, A., Mellado, M. C., Castilho, L. R., Carrondo, M. J., Alves, P. M., Virus-like particles in vaccine development. Expert Rev. Vaccines 2010, 9, 1149-1176.
10. Chackerian, B., Virus-like particles: Flexible platforms for vaccine development. Expert Rev. Vaccines 2007, 6, 381-390.
11. Yildiz, I., Shukla, S., Steinmetz, N. F., Applications of viral nanoparticles in medicine. Curr. Opin. Biotechnol. 2011, 22, 901-908.
12. Pushko, P., Pumpens, P., Grens, E., Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures. Intervirology 2013, 56, 141-165.
13. Scotti, N., Rybicki, E. P., Virus-like particles produced in plants as potential vaccines. Expert Rev. Vaccines 2013, 12, 211-224.
14. Zhao, Q., Li, S., Yu, H., Xia, N., Modis, Y., Virus-like particle-based human vaccines: Quality assessment based on structural and functional properties. Trends Biotechnol. 2013, 31, 654-663.
15. Lua, L. H., Connors, N. K., Sainsbury, F., Chuan, Y. P. et al., Bioengineering virus-like particles as vaccines. Biotechnol. Bioeng. 2014, 111, 425-440.
16. Westaway, E. G., Mackenzie, J. M., Khromykh, A. A., Kunjin RNA replication and applications of Kunjin replicons. Adv. Virus Res. 2003, 59, 99-140.
17. Lindenbach, B. D., Thiel, H. J., Rice, C. M., Flaviviridae: The viruses and their replication. In: Fields Virology. 5th Edition. DM Knipe, PM Howley, Eds. Philadelphia: Lippincott-Raven Publishers. 2007.
18. Gillespie, L. K., Hoenen, A., Morgan, G., Mackenzie, J. M., The endoplasmic reticulum provides the membrane platform for biogenesis of the flavivirus replication complex. J. Virol. 2010, 84, 10438-10447.
19. Welsch, S., Miller, S., Romero-Brey, I., Merz, A. et al., Composition and three-dimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe 2009, 5, 365-375.
20. Paul, D., Bartenschlager, R., Architecture and biogenesis of plus-strand RNA virus replication factories. World J. Virol. 2013, 2, 32-48.
21. Li, L., Lok, S. M., Yu, I. M., Zhang, Y. et al., The flavivirus precursor membrane-envelope protein complex: Structure and maturation. Science 2008, 319, 1830-1834.
22. Zhang, W., Chipman, P. R., Corver, J., Johnson, P. R. et al., Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat. Struct. Biol. 2003, 10, 907-912.
23. Hanna, S. L., Pierson, T. C., Sanchez, M. D., Ahmed, A. A. et al., N-linked glycosylation of west nile virus envelope proteins influences particle assembly and infectivity. J. Virol. 2005, 79, 13262-13274.
24. Allison, S. L., Stadler, K., Mandl, C. W., Kunz, C., Heinz, F. X., Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J. Virol. 1995, 69, 5816-5820.
25. Schalich, J., Allison, S. L., Stiasny, K., Mandl, C. W. et al., Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions. J. Virol. 1996, 70, 4549-4557.
26. Ohtaki, N., Takahashi, H., Kaneko, K., Gomi, Y. et al., Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate. Vaccine 2010, 28, 6588-6596.
27. Konishi, E., Fujii, A., Mason, P. W., Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles. J. Virol. 2001, 75, 2204-2212.
28. Gehrke, R., Ecker, M., Aberle, S. W., Allison, S. L. et al., Incorporation of tick-borne encephalitis virus replicons into virus-like particles by a packaging cell line. J. Virol. 2003, 77, 8924-8933.
29. Zhang, S., Liang, M., Gu, W., Li, C. et al., Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice. Virol. J. 2011, 8, 333.
30. Sugrue, R. J., Fu, J., Howe, J., Chan, Y. C., Expression of the dengue virus structural proteins in Pichia pastoris leads to the generation of virus-like particles. J. Gen. Virol. 1997, 78, 1861-1866.
31. Kuwahara, M., Konishi, E., Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens. Clin. Vaccine Immunol. 2010, 17, 1560-1566.
32. Yamaji, H., Konishi, E., Production of Japanese encephalitis virus-like particles in insect cells. Bioengineered 2013, 4, 438-442.
33. Yamaji, H., Nakamura, M., Kuwahara, M., Takahashi, Y. et al., Efficient production of Japanese encephalitis virus-like particles by recombinant lepidopteran insect cells. Appl. Microbiol. Biotechnol. 2013, 97, 1071-1079.
34. Yamaji, H., Segawa, M., Nakamura, M., Katsuda, T. et al., Production of Japanese encephalitis virus-like particles using the baculovirus-insect cell system. J. Biosci. Bioeng. 2012, 114, 657-662.
35. Qiao, M., Ashok, M., Bernard, K. A., Palacios, G. et al., Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells. J. Infect. Dis. 2004, 190, 2104-2108.
36. Konishi, E., Pincus, S., Paoletti, E., Shope, R. E. et al., Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology 1992, 188, 714-720.
37. Kojima, A., Yasuda, A., Asanuma, H., Ishikawa, T. et al., Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus e protein for a second-generation subunit vaccine. J. Virol. 2003, 77, 8745-8755.
38. Mutoh, E., Ishikawa, T., Takamizawa, A., Kurata, T. et al., Japanese encephalitis subunit vaccine composed of virus-like envelope antigen particles purified from serum-free medium of a high-producer J12#26 cell clone. Vaccine 2004, 22, 2599-2608.
39. Okamoto, S., Yoshii, H., Matsuura, M., Kojima, A. et al., Poly-gamma-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus-like particles provide effective protection from Japanese encephalitis virus. Clin. Vaccine Immunol. 2012, 19, 17-22.
40. Merino-Ramos, T., Blazquez, A. B., Escribano-Romero, E., Canas-Arranz, R. et al., Protection of a single dose west nile virus recombinant subviral particle vaccine against lineage 1 or 2 strains and analysis of the cross-reactivity with Usutu virus. PLoS ONE 2014, 9, e108056.
41. Yauch, L. E., Shresta, S., Mouse models of dengue virus infection and disease. Antiviral Res. 2008, 80, 87-93.
42. Heinz, F. X., Stiasny, K., Flaviviruses and flavivirus vaccines. Vaccine 2012, 30, 4301-4306.
43. Elliott, R. M., Emerging viruses: The Bunyaviridae. Mol. Med. 1997, 3, 572-577.
44. Zheng, W., Tao, Y. J., Genome encapsidation by orthobunyavirus nucleoproteins. Proc. Natl. Acad. Sci. USA 2013, 110, 8769-8770.
45. Elliott, R. M., Molecular biology of the Bunyaviridae. Gen Virol. 1990, 71, 501-522.
46. Rusu, M., Bonneau, R., Holbrook, M. R., Watowich, S. J. et al., An assembly model of rift valley Fever virus. Front. Microbiol. 2012, 3, 254.
47. von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B. et al., Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves. Vaccine 2011, 29, 5771-5777.
48. Hechinger, S., Wernike, K., Beer, M., Single immunization with an inactivated vaccine protects sheep from Schmallenberg virus infection. Vet. Res. 2014, 45, 79.
49. Kortekaas, J., One Health approach to Rift Valley fever vaccine development. Antiviral Res. 2014, 106, 24-32.
50. Kortekaas, J., Ergonul, O., Moormann, R. J., Interventions against West Nile virus, Rift Valley fever virus, and Crimean-Congo hemorrhagic fever virus: Where are we? Vector Borne Zoonotic Dis. 2010, 10, 709-718.
51. Betenbaugh, M., Yu, M., Kuehl, K., White, J. et al., Nucleocapsid- and virus-like particles assemble in cells infected with recombinant baculoviruses or vaccinia viruses expressing the M and the S segments of Hantaan virus. Virus Res. 1995, 38, 111-124.
52. Liu, L., Celma, C. C., Roy, P., Rift Valley fever virus structural proteins: Expression, characterization and assembly of recombinant proteins. Virol J. 2008, 5, 82.
53. Mandell, R. B., Koukuntla, R., Mogler, L. J., Carzoli, A. K. et al., Novel suspension cell-based vaccine production systems for Rift Valley fever virus-like particles. J. Virol. Methods 2010, 169, 259-268.
54. Mandell, R. B., Koukuntla, R., Mogler, L. J., Carzoli, A. K. et al., A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge. Virology 2010, 397, 187-198.
55. Habjan, M., Penski, N., Wagner, V., Spiegel, M. et al., Efficient production of Rift Valley fever virus-like particles: The antiviral protein MxA can inhibit primary transcription of bunyaviruses. Virology 2009, 385, 400-408.
56. Shi, X., Kohl, A., Leonard, V. H., Li, P. et al., Requirement of the N-terminal region of orthobunyavirus nonstructural protein NSm for virus assembly and morphogenesis. J. Virol. 2006, 80, 8089-8099.
57. Naslund, J., Lagerqvist, N., Habjan, M., Lundkvist, A. et al., Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology 2009, 385, 409-415.
58. Koukuntla, R., Mandell, R. B., Flick, R., Virus-like particle-based countermeasures against Rift Valley fever virus. Zoonoses Public Health 2012, 59Suppl2, 142-150.
59. Overby, A. K., Popov, V., Neve, E. P., Pettersson, R. F., Generation and analysis of infectious virus-like particles of uukuniemi virus (bunyaviridae): A useful system for studying bunyaviral packaging and budding. J. Virol. 2006, 80, 10428-10435.
60. de Boer, S. M., Kortekaas, J., Antonis, A. F., Kant, J. et al., Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine 2010, 28, 2330-2339.
61. Latham, T., Galarza, J. M., Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J. Virol. 2001, 75, 6154-6165.
62. Acuna, R., Cifuentes-Munoz, N., Marquez, C. L., Bulling, M. et al., Hantavirus Gn and Gc glycoproteins self-assemble into virus-like particles. J. Virol. 2014, 88, 2344-2348.
63. Weaver, S. C., Winegar, R., Manger, I. D., Forrester, N. L., Alphaviruses: Population genetics and determinants of emergence. Antiviral Res. 2012, 94, 242-257.
64. Enserink, M., Infectious diseases. Crippling virus set to conquer Western Hemisphere. Science 2014, 344, 678-679.
65. Hikke, M. C., Braaen, S., Villoing, S., Hodneland, K. et al., Salmonid glycoprotein E2 requires low temperature and E1 for virion formation and induction of protective immunity. Vaccine 2014, 32, 6206-6212.
66. Hikke, M. C., Verest, M., Vlak, J. M., Pijlman, G. P., Salmonid alphavirus replication in mosquito cells: Towards a novel vaccine production system. Microb. Biotechnol. 2014, 7, 480-484.
67. Kuhn, R. J., Togaviridae: The viruses and their replication. In: Fields Virology. 5th Edition. DM Knipe, PM Howley, Eds. Philadelphia: Lippincott-Raven Publishers. 2007, 1001-1022.
68. Frolova, E., Frolov, I., Schlesinger, S., Packaging signals in alphaviruses. Virol. 1997, 71, 248-258.
69. Voss, J. E., Vaney, M. C., Duquerroy, S., Vonrhein, C. et al., Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature 2010, 468, 709-712.
70. Zhang, W., Heil, M., Kuhn, R. J., Baker, T. S., Heparin binding sites on Ross River virus revealed by electron cryo-microscopy. Virology 2005, 332, 511-518.
71. Bredenbeek, P. J., Frolov, I., Rice, C. M., Schlesinger, S., Sindbis virus expression vectors: Packaging of RNA replicons by using defective helper RNAs. J. Virol. 1993, 67, 6439-6446.
72. Frolov, I., Frolova, E., Schlesinger, S., Sindbis virus replicons and Sindbis virus: Assembly of chimeras and of particles deficient in virus RNA. J. Virol. 1997, 71, 2819-2829.
73. Akahata, W., Yang, Z. Y., Andersen, H., Sun, S. et al., A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat. Med. 2010, 16, 334-338.
74. Li, L., Jose, J., Xiang, Y., Kuhn, R. J., Rossmann, M. G., Structural changes of envelope proteins during alphavirus fusion. Nature 2010, 468, 705-708.
75. Sun, S., Xiang, Y., Akahata, W., Holdaway, H. et al., Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization. Elife 2013, 2, e00435.
76. Chang, L. J., Dowd, K. A., Mendoza, F. H., Saunders, J. G. et al., Safety tolerability of chikungunya virus-like particle vaccine in healthy adults: A phase 1 dose-escalation trial. Lancet 2014, 384, 2046-2052.
77. Akahata, W., Nabel, G. J., A specific domain of the Chikungunya virus E2 protein regulates particle formation in human cells: Implications for alphavirus vaccine design. J. Virol. 2012, 86, 8879-8883.
78. van Oers, M. M., Vaccines for viral and parasitic diseases produced with baculovirus vectors. Adv. Virus Res. 2006, 68, 193-253.
79. Metz, S. W., Geertsema, C., Martina, B. E., Andrade, P. et al., Functional processing and secretion of Chikungunya virus E1 and E2 glycoproteins in insect cells. Virol. J. 2011, 8, 353.
80. Metz, S. W., Gardner, J., Geertsema, C., Le, T. T. et al., Effective chikungunya virus-like particle vaccine produced in insect cells. PLoS Negl. Trop. Dis. 2013, 7, e2124.
81. Metz, S. W., Martina, B. E., van den Doel, P., Geertsema, C. et al., Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits. Vaccine 2013, 31, 6092-6096.
82. Gardner, J., Anraku, I., Le, T. T., Larcher, T. et al., Chikungunya Virus Arthritis in Adult Wild-Type Mice. J. Virol. 2010.
83. Wagner, J. M., Pajerowski, J. D., Daniels, C. L., McHugh, P. M. et al., Enhanced production of Chikungunya virus-like particles using a high-pH adapted spodoptera frugiperda insect cell line. PLoS ONE 2014, 9, e94401.
84. Cox, M. M., Recombinant protein vaccines produced in insect cells. Vaccine 2012, 30, 1759-1766.
85. Vicente, T., Roldao, A., Peixoto, C., Carrondo, M. J., Alves, P. M., Large-scale production and purification of VLP-based vaccines. J. Invertebr. Pathol. 2011, 107Suppl, S42-S48.
86. Gotuzzo, E., Yactayo, S., Cordova, E., Efficacy and duration of immunity after yellow fever vaccination: Systematic review on the need for a booster every 10 years. Am. J. Trop. Med. Hyg. 2013, 89, 434-444.
87. Hervas-Stubbs, S., Rueda, P., Lopez, L., Leclerc, C., Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. J. Immunol. 2007, 178, 2361-2369.
88. Quattrocchi, V., Molinari, P., Langellotti, C., Gnazzo, V. et al., Co-inoculation of baculovirus and FMDV vaccine in mice, elicits very early protection against foot and mouth disease virus without interfering with long lasting immunity. Vaccine 2013, 31, 2713-2718.
89. Smith, G. E., Flyer, D. C., Raghunandan, R., Liu, Y. et al., Development of influenza H7N9 virus like particle (VLP) vaccine: Homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine 2013, 31, 4305-4313.
90. Marek, M., van Oers, M. M., Devaraj, F. F., Vlak, J. M., Merten, O. W., Engineering of baculovirus vectors for the manufacture of virion-free biopharmaceuticals. Biotechnol. Bioeng. 2011, 108, 1056-1067.
91. Roehrig, J. T., West nile virus in the United States - a historical perspective. Viruses 2013, 5, 3088-3108.
92. Morens, D. M., Fauci, A. S., Chikungunya at the door-deja vu all over again? N. Engl. J. Med. 2014, 371, 885-887.
93. Saegerman, C., Berkvens, D., Mellor, P. S., Bluetongue epidemiology in the European Union. Emerg. Infect. Dis. 2008, 14, 539-544.
94. Beer, M., Conraths, F. J., van der Poel, W. H., 'Schmallenberg virus' - a novel orthobunyavirus emerging in Europe. Epidemiol. Infect. 2013, 141, 1-8.
95. Guzman, M. G., Harris, E., Dengue, published online September 2014. Epub accessible bot not yet published. doi: 10.1016/S0140-6736(14)60572-9.
96. van Oers, M. M., Pijlman, G. P., Vlak, J. M., Thirty years of baculovirus-insect cell protein expression: From dark horse to mainstream technology. J. Gen. Virol. 2014, doi: 10.1099/vir.0.067108-0.
97. Gammon, D. B., Duraffour, S., Rozelle, D. K., Hehnly, H. et al., A single vertebrate DNA virus protein disarms invertebrate immunity to RNA virus infection. Elife 2014, e02910.
98. Metz, S. W., Feenstra, F., Villoing, S., van Hulten, M. C. et al., Low temperature-dependent salmonid alphavirus glycoprotein processing and recombinant virus-like particle formation. PLoS ONE 2011, 6, e25816.